133 related articles for article (PubMed ID: 9455978)
1. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis.
McCann SJ; Pond SM; James KM; Le Couteur DG
J Neurol Sci; 1997 Dec; 153(1):50-3. PubMed ID: 9455978
[TBL] [Abstract][Full Text] [Related]
2. Genetic analysis of the CYP2D6 gene in patients with Parkinson's disease.
Tsuneoka Y; Matsuo Y; Ichikawa Y; Watanabe Y
Metabolism; 1998 Jan; 47(1):94-6. PubMed ID: 9440484
[TBL] [Abstract][Full Text] [Related]
3. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis.
Christensen PM; Gøtzsche PC; Brøsen K
Pharmacogenetics; 1998 Dec; 8(6):473-9. PubMed ID: 9918130
[TBL] [Abstract][Full Text] [Related]
4. [Polymorphisms in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson's disease].
Durić G; Svetel M; Nikolaevic SI; Dragadević N; Gavrilović J; Kostić VS
Vojnosanit Pregl; 2007 Jan; 64(1):25-30. PubMed ID: 17304721
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphism of cytochrome P450 2D6 in idiopathic Parkinson disease and diffuse Lewy body disease.
Bordet R; Broly F; Destee A; Libersa C
Clin Neuropharmacol; 1994 Oct; 17(5):484-8. PubMed ID: 9316701
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.
Ur Rasheed MS; Mishra AK; Singh MP
Neurochem Res; 2017 Dec; 42(12):3353-3361. PubMed ID: 28871472
[TBL] [Abstract][Full Text] [Related]
7. Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism.
Bon MA; Jansen Steur EN; de Vos RA; Vermes I
Neurosci Lett; 1999 May; 266(2):149-51. PubMed ID: 10353349
[TBL] [Abstract][Full Text] [Related]
8. Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson's disease.
Maraganore DM; Farrer MJ; Hardy JA; McDonnell SK; Schaid DJ; Rocca WA
Mov Disord; 2000 Jul; 15(4):714-9. PubMed ID: 10928584
[TBL] [Abstract][Full Text] [Related]
9. Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson's disease.
Singh M; Khanna VK; Shukla R; Parmar D
Dis Markers; 2010; 28(2):87-93. PubMed ID: 20364044
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 phenotypes and Parkinson's disease risk: a meta-analysis.
Lu Y; Peng Q; Zeng Z; Wang J; Deng Y; Xie L; Mo C; Zeng J; Qin X; Li S
J Neurol Sci; 2014 Jan; 336(1-2):161-8. PubMed ID: 24211060
[TBL] [Abstract][Full Text] [Related]
11. Interaction between GSTM1-null and CYP2D6-deficient alleles in the pathogenesis of Parkinson's disease.
Santt O; Baranova H; Albuisson E; Bignon YJ; Lucotte G
Eur J Neurol; 2004 Apr; 11(4):247-51. PubMed ID: 15061826
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 polymorphism in Parkinson's disease: the Rotterdam Study.
Harhangi BS; Oostra BA; Heutink P; van Duijn CM; Hofman A; Breteler MM
Mov Disord; 2001 Mar; 16(2):290-3. PubMed ID: 11295783
[TBL] [Abstract][Full Text] [Related]
13. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.
Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maraganore DM; Sturman SG; Schapira AH; Williams AC
Lancet; 1992 Jun; 339(8806):1375-7. PubMed ID: 1350805
[TBL] [Abstract][Full Text] [Related]
14. Rarity of debrisoquine hydroxylase gene polymorphism in Chinese patients with Parkinson's disease.
Pang CP; Zhang J; Woo J; Chan D; Law LK; Tong SF; Kwok T; Kay R
Mov Disord; 1998 May; 13(3):529-32. PubMed ID: 9613747
[TBL] [Abstract][Full Text] [Related]
15. Parkinson's disease, CYP2D6 polymorphism, and age.
Payami H; Lee N; Zareparsi S; Gonzales McNeal M; Camicioli R; Bird TD; Sexton G; Gancher S; Kaye J; Calhoun D; Swanson PD; Nutt J
Neurology; 2001 May; 56(10):1363-70. PubMed ID: 11376189
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer.
Lemos MC; Carrilho F; Rodrigues F; Coutinho E; Gomes L; Carvalheiro M; Regateiro FJ
Clin Endocrinol (Oxf); 2007 Aug; 67(2):180-3. PubMed ID: 17547692
[TBL] [Abstract][Full Text] [Related]
17. The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients.
Mann A; Miksys SL; Gaedigk A; Kish SJ; Mash DC; Tyndale RF
Neurobiol Aging; 2012 Sep; 33(9):2160-71. PubMed ID: 21958961
[TBL] [Abstract][Full Text] [Related]
18. Gene-gene and gene-environment interaction on the risk of Parkinson's disease.
Singh NK; Banerjee BD; Bala K; Chhillar M; Chhillar N
Curr Aging Sci; 2014; 7(2):101-9. PubMed ID: 25101650
[TBL] [Abstract][Full Text] [Related]
19. Genotyping of CYP2D6 in Parkinson's disease.
Stefanović M; Topić E; Ivanisević AM; Relja M; Korsić M
Clin Chem Lab Med; 2000 Sep; 38(9):929-34. PubMed ID: 11097352
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 polymorphism and Parkinson's disease susceptibility.
Sabbagh N; Brice A; Marez D; Dürr A; Legrand M; Lo Guidice JM; Destée A; Agid Y; Broly F
Mov Disord; 1999 Mar; 14(2):230-6. PubMed ID: 10091614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
